## Bone Turnover Markers in Osteoporosis **Key Point:** Biochemical markers of bone turnover are classified into resorption markers and formation markers. CTX is the gold standard resorption marker. ### Resorption Markers These are breakdown products of bone collagen released during osteoclastic activity: - **C-terminal telopeptide of type I collagen (CTX)** — most sensitive and widely used - **N-terminal telopeptide of type I collagen (NTX)** — also sensitive but less commonly used - **Pyridinoline and deoxypyridinoline** — older markers, less specific ### Formation Markers These reflect osteoblastic activity: - **P1NP (Procollagen type I N-terminal propeptide)** — most sensitive formation marker - **Alkaline phosphatase** — bone-specific alkaline phosphatase (BSAP) is more specific than total ALP - **Osteocalcin** — reflects osteoblast activity but less specific ### Clinical Use | Marker | Type | Sensitivity | Clinical Use | |--------|------|-------------|---------------| | CTX | Resorption | Highest | Monitoring treatment response, fracture risk prediction | | NTX | Resorption | High | Similar to CTX | | P1NP | Formation | High | Monitoring anabolic therapy | | BSAP | Formation | Moderate | Less commonly used | | Osteocalcin | Formation | Moderate | Research use | **High-Yield:** CTX decreases within 3–6 months of starting antiresorptive therapy (bisphosphonates, denosumab), making it useful for monitoring treatment adherence and response. **Clinical Pearl:** A reduction in CTX by >30% within 3 months of starting therapy predicts good long-term fracture risk reduction. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.